Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
This article is a narrative review of the most current data on bispecific antibodies in B cell non-Hodgkin’s lymphoma and multiple myeloma.
Back to homepage
Tag "immunotherapy"
Management of adverse effects of new monoclonal antibody treatments in acute lymphoblastic leukemia
This article reviews the unique toxicities and adverse effects of blinatumomab and inotuzumab ozogamicin and provide recommendations for prevention of adverse effects as well as the management options for each medication.
Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents
This article discusses the current management of this rare entity and provide an overview of the most relevant molecular findings, whilst illustrating the potential value that prescreening panels can offer, searching for actionable targets (MSI/dMMR, PD-L1, BRAFv600E) to guide therapy with promising agents that could fill a void in this disease.
Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature
This article discusses the role of mAbs in follicular lymphoma and marginal zone lymphoma along with reviewing the current data about the use of biosimilar mAbs in these diseases.
Immunotherapy in inoperable stage III non-small cell lung cancer: a review
This article summarizes the current status and ongoing clinical trials incorporating immunotherapy into the management of inoperable stage III nonsmall cell lung cancer.
